Research analysts at Evercore ISI began coverage on shares of Bruker (NASDAQ:BRKR) in a report released on Wednesday, January 3rd. The firm set an “in-line” rating and a $36.00 price target on the medical research company’s stock. Evercore ISI’s price target suggests a potential upside of 2.95% from the stock’s previous close.
BRKR has been the subject of a number of other research reports. Zacks Investment Research raised shares of Bruker from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a report on Wednesday, November 8th. Bank of America raised shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 price objective for the company in a research note on Friday, November 3rd. Cowen reaffirmed a “hold” rating and set a $29.00 price target on shares of Bruker in a research note on Friday, November 3rd. JPMorgan Chase & Co. raised shares of Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price target for the company in a research note on Friday, November 3rd. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $35.00 price objective on shares of Bruker in a research report on Thursday, December 14th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company’s stock. Bruker has an average rating of “Hold” and an average target price of $32.38.
Bruker (NASDAQ BRKR) opened at $34.97 on Wednesday. Bruker has a 52 week low of $21.83 and a 52 week high of $36.53. The company has a market cap of $5,366.91, a PE ratio of 37.20, a P/E/G ratio of 2.59 and a beta of 1.12. The company has a quick ratio of 1.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.65.
Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The firm had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. During the same quarter in the prior year, the business posted $0.32 EPS. The business’s revenue was up 10.6% compared to the same quarter last year. equities analysts forecast that Bruker will post 1.19 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the business. Koch Industries Inc. raised its position in Bruker by 2,573.5% in the second quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock worth $324,000 after acquiring an additional 322,252 shares during the period. AJO LP purchased a new position in shares of Bruker in the second quarter worth about $46,075,000. Cubist Systematic Strategies LLC increased its stake in shares of Bruker by 186.3% in the second quarter. Cubist Systematic Strategies LLC now owns 16,478 shares of the medical research company’s stock worth $475,000 after purchasing an additional 10,723 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of Bruker by 65.8% in the second quarter. Teachers Advisors LLC now owns 245,720 shares of the medical research company’s stock worth $7,087,000 after purchasing an additional 97,491 shares in the last quarter. Finally, Verition Fund Management LLC increased its stake in shares of Bruker by 95.6% in the second quarter. Verition Fund Management LLC now owns 26,891 shares of the medical research company’s stock worth $776,000 after purchasing an additional 13,140 shares in the last quarter. 65.60% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Bruker (NASDAQ:BRKR) Research Coverage Started at Evercore ISI” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/evercore-isi-begins-coverage-on-bruker-brkr.html.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.